AbCellera Biologics Inc logo

AbCellera Biologics Inc

ABCL
Healthcare|Biotechnology|Canada
$6.79
-0.49 (-6.72%)
DCF (FCF)
$1.87
Tangible Book
$2.81

About

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Stock Price

+59.8%(1Y)

Pipeline Summary

8 total trials
3
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
Active: 2Completed: 5NO_LONGER_AVAILABLE: 1

Active Trials (2)

Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
NCT07118891Vasomotor Symptoms Associated With Menopause
Phase 1Phase 2Active
Enrollment: 136 participants
A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
NCT07108894Healthy Volunteers
Phase 1Active
Enrollment: 40 participants

BioScore

4.4/10
Cautious

Ownership

Recent Insider Trades

Montalbano John S.BUY
2026-05-1420,000 shares @ $4.77
Booth AndrewBUY
2026-02-2742,600 shares @ $3.42
Thermopylae Holdings Ltd.BUY
2026-02-2738,000 shares @ $3.44
Thermopylae Holdings Ltd.BUY
2026-02-26177,457 shares @ $3.27
Montalbano John S.BUY
2025-11-2650,000 shares @ $3.57

Recent News

2026-07-07 21:00:13
2026-07-07 12:43:58
2026-07-06 15:51:39
2026-07-06 14:00:11
2026-07-06 13:29:46
Data last updated: Jul 13, 2026, 12:43 PM